Alar Pharmaceuticals

6785.TWO

4.25 USD

-0.03

-0.70%

Overview

Last close

4.25 usd

Market cap

283.87M usd

52 week high

9.84 usd

52 week low

3.40 usd

Target price

9.2 usd

Valuation

P/E

N/A

Forward P/E

N/A

Price/Sales

3251.4348

Price/Book Value

3.8081

Enterprise Value

217.53M usd

EV/Revenue

2491.3843

EV/EBITDA

413.1064

Key financials

Revenue TTM

87313.67 usd

Gross Profit TTM

67871.87 usd

EBITDA TTM

-5.24M usd

Earnings per Share

-0.04 usd

Dividend

N/A usd

Total assets

79.25M usd

Net debt

N/A usd

About

Alar Pharmaceuticals Inc., a drug development company, focuses on developing long-acting release drug products for CNS disorders and chronic diseases in Taiwan. The company develops ALA-1000 for the treatment of opioid use disorder. Its pre-clinical stage product includes ALA-1300 and ALA-2000 for the treatment of opioid use disorder; ALA-4000 to treat Parkinson's disease; ALA-3000 for treating treatment-resistant depression; and ALA-5000 to treat schizophrenia. Alar Pharmaceuticals Inc. was founded in 2016 and is based in Taichung, Taiwan.